“We could still have a vaccine by the end of this year, early next year” depending on how fast the regulator is moving, he said.
Speaking at an event hosted by the media group Tortoise, the CEO of AstraZeneca stressed that it is common to take breaks in trials caused by “adverse events”, but that “the difference is that the whole world does not ”usually watch.
Other tests were done on the person who fell ill. The data will then be submitted to an independent safety committee who will evaluate them and then decide if testing can be resumed.
When asked if the disease was transverse myelitis – an inflammation of the sheath containing the nerves of the spinal cord – Soriot replied, “We don’t know if it’s transverse myelitis… We don’t know what is. the final diagnosis. Transverse myelitis can be treated with steroids to reduce inflammation, but the condition can be permanent.
AstraZeneca has forged a number of manufacturing partnerships around the world and believes it can manufacture around 3 billion doses. Soriot said he was convinced that in combination with vaccines developed by other pharmaceutical companies, there would be enough vaccines for the entire world population.